4519 CHUGAI PHARMACEUTICAL CO., LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4519

TSE Prime

CHUGAI PHARMACEUTICAL CO., LTD.

8,233

JPY

-239

(-2.82%)

Dec 5, 3:30 pm JST

53.26

USD

Dec 5, 1:30 am EST

Result

ー

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2021	999,759	421,897	419,385	302,995	184.3	76	Feb 3, 2022	IFRS
Dec, 2022	1,259,726	533,309	531,166	374,429	227.6	78	Feb 2, 2023	IFRS
Dec, 2023	1,111,367	439,174	443,821	325,472	197.8	80	Feb 1, 2024	IFRS
Dec, 2024	1,170,611	542,002	543,034	387,317	235.4	98	Jan 30, 2025	IFRS
Dec, 2025 Guidance	1,190,000	ー	ー	ー	－	250	Jan 30, 2025	IFRS
YoY	+1.7%	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2020	Jan 30, 2020	740,000	ー	ー	ー	50*	IFRS
- - - Results	Feb 4, 2021	786,946	301,230	298,188	214,733	55*	IFRS
Dec, 2021	Feb 4, 2021	Available in future release
	Oct 22, 2021
Results	Feb 3, 2022
Dec, 2022	Feb 3, 2022
Results	Feb 2, 2023
Dec, 2023	Feb 2, 2023
Results	Feb 1, 2024
Dec, 2024	Feb 1, 2024
	Oct 25, 2024
Results	Jan 30, 2025
Dec, 2025	Jan 30, 2025	1,190,000	ー	ー	ー	250	IFRS

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	203,005	+3.8	Available in future release
Mar, 2002	211,705	+4.3
Mar, 2003	237,390	+12.1
Dec, 2003 Changed	232,748	－
Dec, 2004	294,670	+26.6
Dec, 2005	327,155	+11.0
Dec, 2006	326,109	-0.3
Dec, 2007	344,808	+5.7
Dec, 2008	326,937	-5.2
Dec, 2009	428,947	+31.2
Dec, 2010	379,509	-11.5
Dec, 2011	373,516	-1.6
Dec, 2012	386,552	+3.5
Dec, 2013	423,652	+9.6
Dec, 2014	461,109	+8.8
Dec, 2015	498,839	+8.2
Dec, 2016	491,780	-1.4
Dec, 2017	534,199	+8.6
Dec, 2018	579,787	+8.5
Dec, 2019	686,184	+18.4
Dec, 2020	786,946	+14.7
Dec, 2021	999,759	+27.0
Dec, 2022	1,259,726	+26.0
Dec, 2023	1,111,367	-11.8
Dec, 2024	1,170,611	+5.3
Dec, 2025 Guidance	1,190,000	+1.7	ー	-100.0	ー	-100.0	－	-100.0

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2023	1,111,367	439,174	39.5	21.34	17.12	0.58	197.8
Dec, 2024	1,170,611	542,002	46.3	21.96	18.71	0.57	235.4
Dec, 2025 Guidance	1,190,000	ー	ー	ー	ー	0.54	－

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,259,726	542,002	543,034	387,317	235.4
Fiscal Year	Dec, 2022	Dec, 2024	Dec, 2024	Dec, 2024	Dec, 2024

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2022	663,779	246,362	244,248	170,276	103.5	40	Feb 2, 2023	IFRS
Jul - Dec, 2023	531,710	228,264	230,165	168,779	102.6	40	Feb 1, 2024	IFRS
Jul - Dec, 2024	617,751	283,807	284,344	201,055	122.2	57	Jan 30, 2025	IFRS
Jul - Dec, 2025 Guidance	611,537	ー	ー	ー	－	125	Jul 24, 2025	IFRS
YoY	-1.0%	－	－	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2022	533,309	98,117	243,582	-145,465	-145,641	222,169	11.88	IFRS
Dec, 2023	439,174	372,635	409,925	-37,290	-139,331	458,674	23.73	IFRS
Dec, 2024	542,002	220,235	447,600	-227,365	-141,006	540,202	24.46	IFRS

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2023	837,555	317,598	321,131	234,266	142.4	72.4	Oct 24, 2023	IFRS
Jan - Sep, 2024	868,538	418,602	417,527	295,758	179.8	76.9	Oct 25, 2024	IFRS
Jan - Sep, 2025	911,640	429,827	427,902	305,602	185.7	ー	Oct 24, 2025	IFRS
YoY	+5.0%	+2.7%	+2.5%	+3.3%	+3.3%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	273,812	121,576	122,690	91,206	55.4	44.4	Feb 1, 2024	IFRS
Jan - Mar, 2024	236,949	99,874	99,889	74,401	45.2	42.1	Apr 24, 2024	IFRS
Apr - Jun, 2024	315,911	158,321	158,801	111,861	68.0	50.1	Jul 25, 2024	IFRS
Jul - Sep, 2024	315,678	160,407	158,837	109,496	66.6	50.8	Oct 25, 2024	IFRS
Oct - Dec, 2024	302,073	123,400	125,507	91,559	55.6	40.9	Jan 30, 2025	IFRS
Jan - Mar, 2025	288,459	136,651	135,829	97,234	59.1	47.4	Apr 24, 2025	IFRS
Apr - Jun, 2025	290,004	136,691	136,001	97,155	59.0	47.1	Jul 24, 2025	IFRS
Jul - Sep, 2025	333,177	156,485	156,072	111,213	67.6	47.0	Oct 24, 2025	IFRS
YoY	+5.5%	-2.4%	-1.7%	+1.6%	+1.5%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	210,426	+18.7	Available in future release
Jan - Mar, 2021	168,817	-5.9
Apr - Jun, 2021	221,412	+17.3
Jul - Sep, 2021	287,264	+37.8
Oct - Dec, 2021	322,266	+53.1
Jan - Mar, 2022	360,335	+113.4
Apr - Jun, 2022	235,612	+6.4
Jul - Sep, 2022	225,284	-21.6
Oct - Dec, 2022	438,495	+36.1
Jan - Mar, 2023	312,240	-13.3
Apr - Jun, 2023	267,417	+13.5
Jul - Sep, 2023	257,898	+14.5
Oct - Dec, 2023	273,812	-37.6
Jan - Mar, 2024	236,949	-24.1
Apr - Jun, 2024	315,911	+18.1
Jul - Sep, 2024	315,678	+22.4
Oct - Dec, 2024	302,073	+10.3
Jan - Mar, 2025	288,459	+21.7
Apr - Jun, 2025	290,004	-8.2
Jul - Sep, 2025	333,177	+5.5	156,485	-2.4	156,072	-1.7	67.6	+1.5

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	438,495	187,007	186,206	131,775	80.1
Fiscal Year	Dec, 2022	Mar, 2022	Mar, 2022	Mar, 2022	Mar, 2022

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2022	865.88	76.2	1,869,758	1,424,387	1,293,352	ー	Feb 2, 2023	IFRS
Dec, 2023	988.01	84.1	1,932,547	1,625,580	1,488,738	ー	Feb 1, 2024	IFRS
Dec, 2024	1,155.56	86.1	2,208,373	1,901,499	1,746,934	ー	Jan 30, 2025	IFRS
Jan - Sep, 2025	ー	86.6	2,183,588	1,890,107	1,753,017	ー	Oct 24, 2025	IFRS

CHUGAI PHARMACEUTICAL CO., LTD.(4519) Financial Results